These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15089806)

  • 1. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.
    Wenzel RR; Mitchell A; Siffert W; Bührmann S; Philipp T; Schäfers RF
    Br J Clin Pharmacol; 2004 May; 57(5):545-51. PubMed ID: 15089806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of moxonidine on cardiac autonomic modulation.
    Kaya D; Barutcu I; Esen AM; Celik A; Onrat E
    Pacing Clin Electrophysiol; 2010 Aug; 33(8):929-33. PubMed ID: 20230461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced hemodynamic responses to physical and mental stress under low-dose rilmenidine in healthy subjects.
    Teixeira de Castro RR; Tibiriçá E; de Oliveira MA; Moreira PB; Catelli MF; Rocha NN; Nóbrega AC
    Cardiovasc Drugs Ther; 2006 Apr; 20(2):129-34. PubMed ID: 16761192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic dose-dependent modulation of cardiac parasympathetic activity by moxonidine, an imidazoline I1-receptor agonist.
    Turcani M
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):524-35. PubMed ID: 19034032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats.
    Wang LG; Gao L; Wang W; Yuan WJ; Wang WZ
    Neurosci Lett; 2007 Oct; 426(2):91-6. PubMed ID: 17889438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans.
    Galloway SD; De Vito G; McClure S; Nimmo MA; McMurray JJ
    Clin Sci (Lond); 2000 Sep; 99(3):223-30. PubMed ID: 11787475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of moxonidine on stress-induced peak blood pressure and renal function: a randomized, double-blind, placebo-controlled crossover study.
    Fauvel JP; Najem R; Maakel N; Pozet N; Laville M
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):495-9. PubMed ID: 9733365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
    El-Mas MM; Omar AG; Helmy MM; Mohy El-Din MM
    Brain Res; 2009 Jan; 1248():96-106. PubMed ID: 19028461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative sympatholysis. Beneficial effects of the alpha 2-adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. McSPI--Europe Research Group.
    Anesthesiology; 1997 Feb; 86(2):346-63. PubMed ID: 9054253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH.
    Bamberger CM; Mönig H; Mill G; Gödde E; Schulte HM
    Exp Clin Endocrinol Diabetes; 1995; 103(3):205-8. PubMed ID: 7584524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion.
    Esler M; Lux A; Jennings G; Hastings J; Socratous F; Lambert G
    J Hypertens; 2004 Aug; 22(8):1529-34. PubMed ID: 15257176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans.
    De Vito G; Galloway SD; Nimmo MA; Maas P; McMurray JJ
    Clin Physiol Funct Imaging; 2002 Jan; 22(1):32-8. PubMed ID: 12003097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.